92 related articles for article (PubMed ID: 3768871)
1. Human autopsy tissue concentrations of mitoxantrone.
Stewart DJ; Green RM; Mikhael NZ; Montpetit V; Thibault M; Maroun JA
Cancer Treat Rep; 1986 Nov; 70(11):1255-61. PubMed ID: 3768871
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of mitoxantrone.
Ehninger G; Proksch B; Heinzel G; Woodward DL
Cancer Treat Rep; 1986 Dec; 70(12):1373-8. PubMed ID: 3791250
[TBL] [Abstract][Full Text] [Related]
3. Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues.
Stewart DJ; Grewaal D; Green RM; Mikhael N; Goel R; Montpetit VA; Redmond MD
Anticancer Res; 1993; 13(6A):1945-52. PubMed ID: 8297100
[TBL] [Abstract][Full Text] [Related]
4. Disposition of mitoxantrone in cancer patients.
Alberts DS; Peng YM; Leigh S; Davis TP; Woodward DL
Cancer Res; 1985 Apr; 45(4):1879-84. PubMed ID: 3978648
[TBL] [Abstract][Full Text] [Related]
5. Human central nervous system and plasma pharmacology of mitoxantrone.
Green RM; Stewart DJ; Hugenholtz H; Richard MT; Thibault M; Montpetit V
J Neurooncol; 1988; 6(1):75-83. PubMed ID: 3397768
[TBL] [Abstract][Full Text] [Related]
6. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
7. Postmortem drug redistribution--human cases related to results in experimental animals.
Hilberg T; Rogde S; Mørland J
J Forensic Sci; 1999 Jan; 44(1):3-9. PubMed ID: 9987863
[TBL] [Abstract][Full Text] [Related]
8. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P-450-induced cytotoxicity of mitoxantrone by formation of electrophilic intermediates.
Mewes K; Blanz J; Ehninger G; Gebhardt R; Zeller KP
Cancer Res; 1993 Nov; 53(21):5135-42. PubMed ID: 8221649
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution of boron in dogs with spontaneous intracranial tumors following borocaptate sodium administration.
Kraft SL; Gavin PR; Leathers CW; DeHaan CE; Bauer WF; Miller DL; Dorn RV; Griebenow ML
Cancer Res; 1994 Mar; 54(5):1259-63. PubMed ID: 8118814
[TBL] [Abstract][Full Text] [Related]
11. Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-melanoma-bearing mice.
Reszka R; Beck P; Fichtner I; Hentschel M; Richter J; Kreuter J
J Pharmacol Exp Ther; 1997 Jan; 280(1):232-7. PubMed ID: 8996201
[TBL] [Abstract][Full Text] [Related]
12. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy.
Li C; Cui J; Wang C; Li Y; Zhang H; Wang J; Li Y; Zhang L; Zhang L; Guo W; Wang Y
Eur J Pharm Biopharm; 2008 Oct; 70(2):657-65. PubMed ID: 18582570
[TBL] [Abstract][Full Text] [Related]
13. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model.
Kaiser MG; Parsa AT; Fine RL; Hall JS; Chakrabarti I; Bruce JN
Neurosurgery; 2000 Dec; 47(6):1391-8; discussion 1398-9. PubMed ID: 11126910
[TBL] [Abstract][Full Text] [Related]
14. NTP Toxicology and Carcinogenesis Studies of Oxymetholone (CAS NO. 434-07-1) in F344/N Rats and Toxicology Studies of Oxymetholone in B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Aug; 485():1-233. PubMed ID: 12571678
[TBL] [Abstract][Full Text] [Related]
15. Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres.
Yemisci M; Bozdag S; Cetin M; Söylemezoglu F; Capan Y; Dalkara T; Vural I
Neurosurgery; 2006 Dec; 59(6):1296-302; discussion 1302-3. PubMed ID: 17277693
[TBL] [Abstract][Full Text] [Related]
16. Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment.
Alexiou C; Jurgons R; Schmid RJ; Bergemann C; Henke J; Erhardt W; Huenges E; Parak F
J Drug Target; 2003 Apr; 11(3):139-49. PubMed ID: 13129824
[TBL] [Abstract][Full Text] [Related]
17. NTP Toxicology and Carcinogenesis Studies of Methyleugenol (CAS NO. 93-15-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2000 Jul; 491():1-412. PubMed ID: 12563349
[TBL] [Abstract][Full Text] [Related]
18. The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone.
Trédan O; Garbens AB; Lalani AS; Tannock IF
Cancer Res; 2009 Feb; 69(3):940-7. PubMed ID: 19176397
[TBL] [Abstract][Full Text] [Related]
19. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
20. Redistribution of basic drugs into cardiac blood from surrounding tissues during early-stages postmortem.
Moriya F; Hashimoto Y
J Forensic Sci; 1999 Jan; 44(1):10-6. PubMed ID: 9987864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
